Business
GB Sciences Files Patent Application for Chronic Pain and Heart Therapies
GB Sciences Files Patent Application for Chronic Pain and Heart Therapies.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Files Patent Application for Chronic Pain and Heart Therapies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Files Patent Application for Chronic Pain and Heart Therapies\nPR Newswire\nLAS VEGAS, May 23, 2017\n\n\n\nLAS VEGAS, May 23, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures (\"MCCM\").   \n\n\n \n \n\n \nThe current US opioid epidemic, along with growing public and government concern regarding opioid abuse, makes new pain treatments a promising field of research and development. Our novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (\"THC\"), which minimizes their potential for abuse. Pain management represents an estimated health burden of between $560 to $650 billion dollars for chronic pain and between $17 to $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, our novel heart disease formulations address the $316 billion dollar heart therapy market in the US.\n\nOur current drug discovery efforts were accelerated through the powerful combination of GB Sciences' proprietary in silico prediction approach, termed the GB Sciences' Network Pharmacology Platform (\"NPP\"), and GB Sciences' proven high-throughput screening techniques using cell-based models. The current provisional patent application covers myrcene-containing complex mixtures capable of targeting the non-traditional cannabinoid receptor, TRPV1. Our latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016. \n\n\"Many cannabis researchers have theorized that the role of terpenes in cannabis-based therapies is to act as so-called 'Entourage' components. We show that the TRPV1 receptor is a target for these 'Entourage' compounds, a molecular interaction that had previously been demonst...